

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal646jxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
DWPI and DPCI

NEWS EXPRESS July 11 CURRENT WINDOWS VERSION IS V6.0b,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:35:52 ON 09 AUG 2001

=> file medline, caplus, embase, biosis

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.45	0.45

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 08:36:45 ON 09 AUG 2001

FILE 'CAPLUS' ENTERED AT 08:36:45 ON 09 AUG 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 08:36:45 ON 09 AUG 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 08:36:45 ON 09 AUG 2001
COPYRIGHT (C) 2001 BIOSIS(R)

=> s cd40l or cd154 or gp39 or t-bam or rankl or trance or opgl or odf or
cd27l or cd70

L1 8035 CD40L OR CD154 OR GP39 OR T-BAM OR RANKL OR TRANCE OR OPGL OR
ODF OR CD27L OR CD70

=> s collectins or SPD

L2 3629 COLLECTINS OR SPD

=> s l1 and l2

L3 2 L1 AND L2

=> duplicate remove

ENTER L# LIST OR (END):13

PROCESSING COMPLETED FOR L3

L4 2 DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)

=> d l4 1- ibib, abs

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:507866 CAPLUS

TITLE: Multimerization domain-containing fusion proteins and
use of fusion protein multimers for therapy and
diagnosis

INVENTOR(S): Tschopp, Juerg; Schneider, Pascal; Holler, Nils

PATENT ASSIGNEE(S): Apotech Research and Development Ltd., Switz.

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049866	A1	20010712	WO 2000-EP13032	20001220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19963859	A1	20010712	DE 1999-19963859	19991230
-------------	----	----------	------------------	----------

PRIORITY APPLN. INFO.: DE 1999-19963859 A 19991230

AB The invention relates to oligomers of a dimer, trimer, quatromer or
pentamer of recombinant fusion proteins. Said oligomers are
characterized

in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biol. function, in particular with a ligand function for antibodies, for sol. or membranous signal mols., for receptors or an antibody, or an antibody segment, and component B contains

a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party mols. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion

proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence. Thus, component A may be Fas ligand, TRAIL, tumor necrosis factor .alpha., or CD40L while component B may be an ACRP30 or cytokine EDA domain. Fusion proteins contg. the above components were prepd. and tested for biol. activity.

REFERENCE COUNT: 10

REFERENCE(S): (1) Beth Israel Hospital; WO 9902711 A 1999 CAPLUS
(2) Filpula, D; US 5763733 A 1998 CAPLUS
(3) Harvard College; WO 9942597 A 1999 CAPLUS
(4) Kishore, U; BIOCHEMICAL JOURNAL 1998, V333(1),

P27

CAPLUS

(5) Protein Design Labs Inc; WO 9733617 A 1997 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:435124 CAPLUS

DOCUMENT NUMBER: 135:45182

TITLE: Multimeric forms of TNF superfamily ligands

INVENTOR(S): Kornbluth, Richard S.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042298	A1	20010614	WO 2000-US7380	20000320

W: AU, CA, JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1999-454223 A 19991209

AB A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL /TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these sol. fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its

potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be esp. useful when these proteins are injected locally as a vaccine adjuvant

or tumor immunotherapy agent to prevent them from diffusing away. In addn., these and other TNFSF-collecting fusion proteins present new possibilities for the expression of highly active, multimeric, sol. TNFSF members.

REFERENCE COUNT: 2

REFERENCE(S):

(1) Gires, O; EMBO J 1999, V16(20), P6131

(2) Pison, U; Eur J Clin Inv 1994, V24(9), P586

CAPLUS

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
28.27	28.72

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.18	-1.18

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 08:41:11 ON 09 AUG 2001